| Literature DB >> 29695883 |
Christophe Van Dijck1, Erika Vlieghe2, Janneke Arnoldine Cox3.
Abstract
OBJECTIVE: To review the effectiveness of antibiotic stewardship interventions in hospitals in low- and middle-income countries.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29695883 PMCID: PMC5872012 DOI: 10.2471/BLT.17.203448
Source DB: PubMed Journal: Bull World Health Organ ISSN: 0042-9686 Impact factor: 9.408
Fig. 1Flowchart of the selection of studies included in the review of antibiotic stewardship interventions in hospitals in low-and middle-income countries
Characteristics of studies included in the review of antibiotic stewardship interventions in hospitals in low-and middle-income countries
| Authors, year | Study design | Country | Setting | Participants | Intervention type | Intervention details | Target illness |
|---|---|---|---|---|---|---|---|
| Weinberg et al., 2001 | Interrupted time-series | Colombia | 2 referral hospitals | Surgeons performing caesarean sections | Bundle | Guidelines on surgical antibiotic prophylaxis; structural changes (availability of prophylactic antibiotics on site); audit and feedback to physicians and nurses at hospital and individual level | Surgical site infections after caesarean section |
| Perez et al., 2003 | Interrupted time-series | Colombia | 2 university hospitals | Hospital A: all prescribers; hospital B: anaesthesiologists | Bundle | Prescription form with (un)restricted antibiotics; educational campaign; reminders in the workplace | NR |
| Gülmezoglu et al., 2007 | Cluster randomized controlled trial | Mexico and Thailand | 22 non-university maternity hospitals | Physicians, midwives, interns, students | Structural | Access to WHO’s online Reproductive Health Library | Surgical site infections after caesarean section |
| Hadi et al., 2008 | Interrupted time-series | Indonesia | 1 teaching hospital | All prescribers of 5 internal medicine wards | Enabling | Antibiotic guidelines; education for prescribers | NR |
| Özkaya et al., 2009 | Non-randomized controlled trial | Turkey | 1 university hospital | Paediatric emergency department residents | Structural | Antibiotic initiation guided by influenza rapid test versus no laboratory investigation | Mild influenza-like illness |
| Rattanaumpawan et al., 2010 | Non-randomized controlled trial | Thailand | 1 public university hospital | All prescribers | Persuasive | Audit and feedback to prescribers by infectious diseases specialist | NR |
| Long et al., 2011 | Randomized controlled trial | China | 1 university hospital | Emergency department physicians | Structural | Antibiotic initiation and discontinuation guided by serum procalcitonin level versus routine carea | Community-acquired pneumonia |
| Maravić-Stojković et al., 2011 | Randomized controlled trial | Serbia | 1 tertiary hospital | Cardiac surgery and intensive care unit staff | Structural | Antibiotic initiation guided by serum procalcitonin level versus routine care (based on clinical signs, C-reactive protein levels and leukocyte count) | Infections after coronary artery bypass grafting or valve surgery |
| Shen et al., 2011 | Cluster randomized controlled trial | China | 1 tertiary hospital | All prescribers of 2 pulmonary wards | Persuasive | Audit and feedback to prescribers by clinical pharmacist | Respiratory tract infections |
| Opondo et al., 2011 | Cluster randomized controlled trial | Kenya | 8 district hospitals | Nurses, clinical and medical officers | Bundle | Guidelines for treatment of non-bloody diarrhoea; education for prescribers; audit and feedback to prescribers on hospital performance | Non-bloody diarrhoea |
| Bucher et al., 2012 | Randomized controlled trial | Peru | 1 public hospital | Paediatric emergency department physicians | Structural | Antibiotic initiation guided by faecal rotavirus rapid test in combination with a faecal leukocyte test versus faecal leukocyte test only | Acute diarrhoea |
| Magedanz et al., 2012 | Interrupted time-series | Brazil | 1 university hospital | All prescribers of the cardiology department | Bundle | Restriction of certain antibiotics; audit and feedback to prescribers by (i) infectious diseases specialist and (ii) pharmacist | NR |
| Qu et al., 2012 | Randomized controlled trial | China | 1 municipal hospital | Intensive care unit staff | Structural | Antibiotic initiation and discontinuation guided by serum procalcitonin level versus standard 14 days of antibiotics | Severe acute pancreatitis |
| Ding et al., 2013 | Randomized controlled trial | China | 1 tertiary hospital | Respiratory ward physicians | Structural | Antibiotic initiation and discontinuation guided by serum procalcitonin level versus routine care (based on clinical experience, sputum bacteriology results and leukocyte count) | Acute exacerbation of idiopathic pulmonary fibrosis |
| Aiken et al., 2013 | Interrupted time-series | Kenya | 1 public referral hospital | Nursing, medical and operating theatre staff | Bundle | Guidelines on surgical antibiotic prophylaxis; clinician education; patient education posters; audit and feedback to prescribers | Surgical site infections |
| Oliveira et al., 2013 | Randomized controlled trial | Brazil | 2 public university hospitals | Intensive care unit staff | Structural | Antibiotic discontinuation guided by serum procalcitonin level versus C-reactive protein test | Sepsis or septic shock |
| Tang et al., 2013 | Randomized controlled trial | China | 1 university hospital | Emergency department physicians | Structural | Antibiotic initiation guided by serum procalcitonin level versus routine carea | Acute asthma exacerbation |
| Chandy et al., 2014 | Interrupted time-series | India | 1 private tertiary hospital | All prescribers | Enabling | Implementation and dissemination of antibiotic prescribing guidelines | NR |
| Long et al., 2014 | Randomized controlled trial | China | 1 university hospital | Emergency department physicians | Structural | Antibiotic initiation guided by serum procalcitonin level versus routine carea | Acute asthma exacerbation |
| Najafi et al., 2015 | Randomized controlled trial | Islamic Republic of Iran | 1 university hospital | Intensive care unit staff | Structural | Antibiotic initiation guided by serum procalcitonin level versus routine carea | Severe inflammatory response syndrome |
| Bao et al., 2015 | Interrupted time-series | China | 65 public hospitals (30 tertiary; 35 secondary) | All prescribers | Bundle | Implementation of a nationally imposed multifaceted antibiotic stewardship programme | NR |
| Sun et al., 2015 | Interrupted time-series | China | 15 public tertiary hospitals | All prescribers | Bundle | Implementation of a nationally imposed multifaceted antibiotic stewardship programme | NR |
| Gong et al., 2016 | Interrupted time-series | China | 1 tertiary paediatric hospital | Paediatricians | Bundle | Antibiotic guidelines and prescribing restrictions; audit and feedback to prescribers by pharmacists and infection control physicians; financial penalties according to number of noncompliant prescriptions | NR |
| Brink et al., 2016 | Interrupted time-series | South Africa | 47 private hospitals | Physicians, other clinical staff and managers | Persuasive | Audit and feedback to prescribers by a pharmacist | NR |
| Li et al., 2017 | Non-randomized controlled trial | China | 6 university hospitals | Physicians of 8 intensive care units | Persuasive | Audit and feedback to prescribers by a pharmacist versus no intervention | NR |
| Tuon et al., 2017 | Interrupted time-series | Brazil | 1 university hospital | All prescribers | Structural | Mobile phone application providing antibiotic prescribing guidance | NR |
| Wattal et al., 2017 | Interrupted time-series | India | 1 tertiary hospital | Surgeons of 45 units | Persuasive | Audit and feedback to prescribers; focus group discussions per specialty | NR |
NR: not reported; WHO: World Health Organization.
a The content of routine care was not specified.
Fig. 2Assessment of risk of bias in studies included in the review of antibiotic stewardship interventions in hospitals in low-and middle-income countries
Outcomes of interventions to improve appropriate prescribing and use of antibiotics in hospitals in low-and middle-income countries: controlled trials
| Intervention type and study design | Study duration, weeks | No. of patients | Data summary | Outcome measure | Effect size | |
|---|---|---|---|---|---|---|
| Procalcitonin guidance | ||||||
| Randomized controlled trial | 201 | 172 | No. of patients receiving antibiotics: 72/86 in procalcitonin group; 79/86 in routine care group | RR of receiving antibiotic (95% CI) | 0.87 (0.79 to 0.96) | 0.01 |
| Randomized controlled trial | NR | 205 | No. of patients receiving antibiotics: 19/102 in procalcitonin group; 48/103 in routine care group | RR of receiving antibiotic (95% CI) | 0.40 (0.25 to 0.63) | 0.01 |
| No. of deaths: 3/102 in procalcitonin group; 3/103 in routine care group | RR of in-hospital death (95% CI) | 0.88 (0.33 to 2.35) | 0.80 | |||
| Randomized controlled trial | 154 | 78 | No. of patients receiving antibiotics: 26/39 in procalcitonin group; 35/39 in routine care group | RR of receiving antibiotic (95% CI) | 0.74 (0.58 to 0.95) | 0.01 |
| No. of deaths: 21/39 in procalcitonin group; 20/39 in routine care group | RR of death after 30 daysa (95% CI) | 1.11 (0.76 to 1.64) | 0.42 | |||
| Randomized controlled trial | 133 | 71 | No. of deaths: 7/35 in procalcitonin group; 8/36 in standard 14 days of antibiotics group | RR of in-hospital death (95% CI) | 0.90 (0.37 to 2.22) | 0.99 |
| Randomized controlled trial | 141 | 97 | No. of deaths: 21/50 in procalcitonin group; 21/47 in routine care group | RR of in-hospital death (95% CI) | 0.92 (0.59 to 1.44) | 0.84 |
| Randomized controlled trial | 283 | 265 | No. of patients receiving antibiotics: 59/132 in procalcitonin group; 95/133 in routine care group | RR of receiving antibiotic (95% CI) | 0.63 (0.50 to 0.78) | 0.01 |
| Randomized controlled trial | 133 | 180 | No. of patients receiving antibiotics: 44/90 in procalcitonin group; 79/90 in routine care group | RR of receiving antibiotic (95% CI) | 0.56 (0.44 to 0.70) | 0.01 |
| Randomized controlled trial | 52 | 60 | No. of deaths: 5/30 in procalcitonin group; 4/30 in routine care group | RR of in-hospital death (95% CI) | 1.25 (0.37 to 4.21) | 0.71 |
| Rapid diagnostic testing | ||||||
| Non-randomized controlled trial | 21 | 97 | No. of patients receiving antibiotics: 34/50 in influenza rapid diagnostic test group; 47/47 in routine care group | RR of receiving antibiotic (95% CI) | 0.68 (0.56 to 0.82) | 0.01 |
| Randomized controlled trial | 26 | 201 | No. of patients receiving antibiotics: 29/100 in faecal leukocyte + rotavirus rapid test group; 50/101 in faecal leukocyte test only group | RR of receiving antibiotic (95% CI) | 0.59 (0.41 to 0.84) | 0.03 |
| Library access plus workshops | ||||||
| Cluster randomized controlled trial | 43 to 52b | 1000 to 1022 per hospital | Mean % of operations with antibiotic prophylaxis: | % of operations with antibiotic prophylaxis: difference in adjusted rate (95% CI) | Mexico: 19 (−8 to 46) | 0.12 |
| Thailand: 5 (−18 to 27) | 0.66 | |||||
| Audit and feedback on individual patient cases | ||||||
| Non-randomized controlled trial | 17 | 948 | Mean no. of days of hospitalization: 30.4 in intervention group; 30.7 in control group | Mean difference in hospital length of stay (95% CI), days | −0.3 (−3.3 to −3.0) | 0.80 |
| Mean no. of days of treatment: 12.7 in intervention group; 16.4 in control group | Mean difference in treatment duration, days | −3.7 (−5.2 to −2.2) | 0.01 | |||
| Cluster randomized controlled tria | 43 | 436 | Mean no. of days of hospitalization: 14.2 in intervention group; 15.8 in control group | Mean difference in hospital length of stay (95% CI), days | −1.6 (−2.9 to −0.3) | 0.03 |
| Non-randomized controlled trial | 9 | 874 | Median no. of days of treatment: 4.0 in intervention group; 5.0 in control group | Difference in median no. of days of treatment | 1.0 | 0.03 |
| Treatment guidelines plus education plus audit and feedback | ||||||
| Cluster randomized controlled trial | 77 | 1160 | No. of patients receiving antibiotics for inappropriate indication: 313/594 in intervention group; 437/566 in control group | Absolute risk reduction for receiving antibiotic for inappropriate indication (95% CI) | 41 (−6 to 88) | 0.08 |
CI: confidence interval; DDD: defined daily doses; NR: not reported; RR: relative risk.
a Per protocol analysis.
b Different collection periods in different hospitals.
Note: Intention-to-treat analysis results are reported unless indicated otherwise. When significant P-values were not specified, we assumed P < 0.05 as significant.
Outcomes of interventions to improve appropriate prescribing and use of antibiotics in hospitals in low-and middle-income countries: interrupted time-series studies
| Intervention | Study segments (duration in weeks) | No. of data points per segment (no. of observations per data point) | Outcome measure | Effect sizea | |
|---|---|---|---|---|---|
| Mobile phone application | S1: Pre-intervention (52) | 12 (NR) | DDD per 1000 bed-days | Baseline trend NR | N/A |
| S2: Post-intervention (52) | 12 (NR) | Trend increased for amikacinb | 0.02 | ||
| Trend increased for cefepimeb | 0.01 | ||||
| Trend decreased for piperacillinb | 0.02 | ||||
| Trend decreased for meropenemb | 0.44 | ||||
| Trend decreased for polymyxinb | 0.34 | ||||
| Trend decreased for ciprofloxacinb | 0.08 | ||||
| Audit and feedback on individual patient cases | S1: Pre-intervention (70) | 16 (NR) | DDD per 100 bed-days | Baseline level NR | N/A |
| Baseline trend +0.064/month | 0.62 | ||||
| S2: Implementation (104) | 24 (NR) | Level change NR | N/A | ||
| Trend change −0.56/month | 0.01 | ||||
| S3: Post-intervention (86) | 20 (NR) | Level change NR | N/A | ||
| Trend change −0.20/month | 0.05 | ||||
| Audit and feedback at department level | S1: Pre-intervention (52) | 12 (NR) | DDD per 100 bed-days | Baseline level: NR | N/A |
| Baseline trend: increasing in 1/35 wardsb | 0.05 | ||||
| S2: Post-intervention (13) | 3 (NR) | Level decreased in 3/35 wardsb | 0.05 | ||
| Treatment guidelines | S1: Pre-intervention (16) | 9 (14) | DDD per 100 bed-days | Baseline level: NR | N/A |
| Baseline trend: −1.0 per 14 days | 0.53 | ||||
| S2: Guideline development (14) | 6 (14) | Level change: −31.9 | 0.03 | ||
| Trend change +2.1 per 14 days | 0.52 | ||||
| S3: Guideline declaration (8) | 4 (26) | Level change: −29.2 | 0.11 | ||
| Trend change: −9.5 per 14 days | 0.14 | ||||
| S4: Teaching sessions (8) | 4 (27) | Level change: +38.2 | 0.05 | ||
| Trend change: +10.0 per 14 days | 0.21 | ||||
| S5: Refresher course (8) | 5 (15) | Level change: −2.4 | 0.88 | ||
| Trend change: −9.8 per 14 days | 0.15 | ||||
| Treatment guidelines | S1: Pre-intervention (86) | 20 (NR) | DDD per 100 bed-days | Baseline level: 56.9 | N/A |
| Baseline trend: +0.95 per month | 0.01 | ||||
| S2: Guideline preparation and booklet dissemination (94) | 22 (NR) | Level change: NR | N/A | ||
| Trend change: +0.21 per month | 0.03 | ||||
| S3: No new intervention (104) | 24 (NR) | Level change: NR | N/A | ||
| Trend change: +0.31 per month | 0.01 | ||||
| S4: Guideline revision and booklet dissemination (104) | 24 (NR) | Level change: NR | N/A | ||
| Trend change: +0.05 per month | 0.64 | ||||
| S5: Guideline revision and booklet with electronic dissemination (86) | 20 (NR) | Level change: NR | N/A | ||
| Trend change: −0.37 per month | 0.01 | ||||
| Treatment guidelines plus structural changes | |||||
| S1: Pre-intervention (13) | 3 (308) | % of operations with surgical site infection | Baseline level: 13.9 | N/A | |
| Baseline trend: NRc | NR | ||||
| S2: Guideline introduction with structural changes (30) | 7 (272) | Level change: −9.8 | 0.01 | ||
| Trend change: NRc | NR | ||||
| S3: Post-intervention (21) | 5 (217) | Level change: NRc | NR | ||
| Trend change: NRc | NR | ||||
| S1: Pre-intervention (13) | 3 (308) | % of caesarean sections with administration of antibiotic prophylaxis | Baseline level: 47.5 | N/A | |
| Baseline trend: NRc | NR | ||||
| S2: Guideline introduction with structural changes (30) | 7 (272) | Level change: +31.6 | 0.01 | ||
| Trend change: NRc | NR | ||||
| S3: Post-intervention (21) | 5 (217) | Level change: −4.9 | 0.01 | ||
| Trend change: NRc | NR | ||||
| S1: Pre-intervention (13) | 3 (396) | % of caesarean sections with administration of antibiotic prophylaxis | Baseline level: 5.1 | N/A | |
| Baseline trend: NRc | NR | ||||
| S2: Guideline introduction with structural changes (39) | 9 (1026) | Level change: NRc | NR | ||
| Trend change: +5.4 per month | 0.01 | ||||
| S3: Post-intervention (52) | 12 (709) | Level change: +7.1 | 0.05 | ||
| Trend change: −4.1 | 0.01 | ||||
| S1: Pre-intervention (13) | 3 (308) | % of caesarean sections with administration of antibiotic prophylaxis within 1 hour of delivery | Baseline level: 32.5 | N/A | |
| Baseline trend: NRc | NR | ||||
| S2: Guideline introduction with structural changes (30) | 7 (272) | Level change: 62.2 | 0.01 | ||
| Trend change: NRc | 0.01 | ||||
| S3: Post-intervention (21) | 5 (217) | Level change: NRc | NR | ||
| Trend change: NRc | NR | ||||
| S1: Pre-intervention (13) | 3 (396) | % of caesarean sections with administration of antibiotic prophylaxis within 1 hour of delivery | Baseline level: 30.8 | N/A | |
| Baseline trend: +18.4 per month | 0.01 | ||||
| S2: Guideline introduction with structural changes (39) | 9 (1026) | Level change: NRc | NR | ||
| Trend change: −18.7 per month | 0.01 | ||||
| S3: Post-intervention (52) | 12 (709) | Level change: +15.2 | NR | ||
| Trend change: NRc | NR | ||||
| Prescription form plus education plus reminders | S1: Pre-intervention (103) | 103 (NR) | % of operations with incorrect timing of antibiotic prophylaxis | Baseline level: NR | N/A |
| Baseline trend: NR | N/A | ||||
| S2: Post-intervention (42) | 42 (NR) | Level change: −20 | 0.01 | ||
| Trend change: NR | NR | ||||
| Antibiotic restrictions plus audit and feedback | S1: Pre-intervention (129) | 30 (NR) | Antibiotic use, DDD per 100 bed-days | Baseline level: NR | N/A |
| Baseline trend +1.2 per month | 0.01 | ||||
| S2: Antibiotic restrictions plus audit and feedback by infectious diseases specialist (94) | 22 (NR) | Level change: −1.3 | 0.8 | ||
| Trend change: −2.7 per month | 0.01 | ||||
| S3: Antibiotic restrictions plus audit and feedback by pharmacist (86) | 20 (NR) | Level change: +4.7 | 0.4 | ||
| Trend change: +1.2 per month | 0.01 | ||||
| Treatment guidelines plus education plus audit and feedback | |||||
| S1: Pre-intervention (26) | 26 (NR) | % of operations with incorrect timing of antibiotic prophylaxis | Baseline level: 99% | N/A | |
| Baseline trend: NR | N/A | ||||
| S2: Post-intervention (40) | 40 (NR) | Level decreasedb | 0.01 | ||
| Trend decreasedb | 0.01 | ||||
| S1: Pre-intervention (26) | 6 (223) | % of operations with surgical site infection | Baseline level: NR | N/A | |
| Baseline trend: −0.5 per month | 0.49 | ||||
| S2: Post-intervention (39) | 9 (223) | Level change: NR | 0.05 | ||
| Trend change: −0.7 per month | 0.03 | ||||
| Multifaceted antibiotic stewardship programme | |||||
| S1: Pre-intervention (52) | 12 (NR) | % of patients receiving antibiotic | Baseline level: NR | N/A | |
| Baseline trend +0.3 per month | > 0.05 | ||||
| S2: Implementation (52) | 12 (NR) | Level change: −2.3 | > 0.05 | ||
| Trend change: −2.3 per month | 0.01 | ||||
| S3: Post-intervention (104) | 24 (NR) | Level change: −2.7 | 0.05 | ||
| Trend change: +1.9 per month | 0.01 | ||||
| S1: Pre-intervention (52) | 12 (NR) | Antibiotic use, DDD per 100 bed-days | Baseline level: NR | N/A | |
| Baseline trend: −0.4 per month | 0.2 | ||||
| S2: Implementation (52) | 12 (NR) | Level change: +2.8 | > 0.05 | ||
| Trend change: −2.2 per month | 0.01 | ||||
| S3: Post-intervention (104) | 24 (NR) | Level change: −7.1 | 0.01 | ||
| Trend change: +2.4 per month | 0.01 | ||||
| Multifaceted antibiotic stewardship programme | S1: Pre-intervention (334) | 26 (58) | % of patients receiving antibiotic | Baseline level: 74.7 | N/A |
| Baseline trend: −0.3 per quarter | 0.01 | ||||
| S2: Post-intervention (78) | 6 (750) | Level change: −7.3 | 0.04 | ||
| Trend change: −1.5 per quarter | 0.07 | ||||
| Treatment guidelines plus antibiotic restrictions plus audit and feedback | S1: Pre-intervention (17) | 4 (375 985) | % of patients receiving antibiotic | Baseline level: 59.0 | N/A |
| Baseline trend: −3.0 per month | 0.01 | ||||
| S2: Guidelines and restrictions (21) | 5 (424 702) | Level change: +3.0 | 0.2 | ||
| Trend change: −0.4 per month | 0.6 | ||||
| S3: Financially punished audit and feedback (60) | 14 (446 727) | Level change: −9.0 | 0.01 | ||
| Trend change: +3.0 per month | 0.01 |
DDD: defined daily doses; N/A: not applicable; NR: not reported; RR: relative risk; S: segment.
a In interrupted times-series studies the linear curve which summarizes the outcome data in each study segment can be defined by its level (y-intercept) and trend (slope). Level change reflects the difference of the level of the current segment compared with the level of the previous segment. Trend change reflects the difference of the trend of the current segment compared to the trend of the previous segment.
b The authors reported no values for level or trend changes.
c The authors reported that there were no significant changes but with no values for levels or trend changes.